These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 28485764)

  • 21.
    Pissa M; Helkkula T; Appelqvist F; Silander G; Borg Å; Pettersson J; Lapins J; Nielsen K; Höiom V; Helgadottir H
    Acta Oncol; 2021 Jul; 60(7):888-896. PubMed ID: 33945383
    [No Abstract]   [Full Text] [Related]  

  • 22. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants.
    Puntervoll HE; Yang XR; Vetti HH; Bachmann IM; Avril MF; Benfodda M; Catricalà C; Dalle S; Duval-Modeste AB; Ghiorzo P; Grammatico P; Harland M; Hayward NK; Hu HH; Jouary T; Martin-Denavit T; Ozola A; Palmer JM; Pastorino L; Pjanova D; Soufir N; Steine SJ; Stratigos AJ; Thomas L; Tinat J; Tsao H; Veinalde R; Tucker MA; Bressac-de Paillerets B; Newton-Bishop JA; Goldstein AM; Akslen LA; Molven A
    J Med Genet; 2013 Apr; 50(4):264-70. PubMed ID: 23384855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients.
    Dalmasso B; Pastorino L; Ciccarese G; Andreotti V; Grillo F; Mastracci L; Spagnolo F; Ballestrero A; Queirolo P; Bruno W; Ghiorzo P
    J Am Acad Dermatol; 2019 May; 80(5):1263-1271. PubMed ID: 30274933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis.
    Fargnoli MC; Gandini S; Peris K; Maisonneuve P; Raimondi S
    Eur J Cancer; 2010 May; 46(8):1413-20. PubMed ID: 20189796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family.
    Maubec E; Chaudru V; Mohamdi H; Blondel C; Margaritte-Jeannin P; Forget S; Corda E; Boitier F; Dalle S; Vabres P; Perrot JL; Lyonnet DS; Zattara H; Mansard S; Grange F; Leccia MT; Vincent-Fetita L; Martin L; Crickx B; Joly P; Thomas L; ; Bressac-de Paillerets B; Avril MF; Demenais F
    J Am Acad Dermatol; 2012 Dec; 67(6):1257-64. PubMed ID: 22841127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumours associated with BAP1 mutations.
    Murali R; Wiesner T; Scolyer RA
    Pathology; 2013 Feb; 45(2):116-26. PubMed ID: 23277170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population.
    Landi MT; Kanetsky PA; Tsang S; Gold B; Munroe D; Rebbeck T; Swoyer J; Ter-Minassian M; Hedayati M; Grossman L; Goldstein AM; Calista D; Pfeiffer RM
    J Natl Cancer Inst; 2005 Jul; 97(13):998-1007. PubMed ID: 15998953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
    Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
    Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline BAP1 alterations in familial uveal melanoma.
    Rai K; Pilarski R; Boru G; Rehman M; Saqr AH; Massengill JB; Singh A; Marino MJ; Davidorf FH; Cebulla CM; H Abdel-Rahman M
    Genes Chromosomes Cancer; 2017 Feb; 56(2):168-174. PubMed ID: 27718540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [From gene to disease; from p16 to melanoma].
    Gruis NA; Bergman W
    Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pediatric melanoma in melanoma-prone families.
    Goldstein AM; Stidd KC; Yang XR; Fraser MC; Tucker MA
    Cancer; 2018 Sep; 124(18):3715-3723. PubMed ID: 30207590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ocular melanoma and the BAP1 hereditary cancer syndrome: implications for the dermatologist.
    Martorano LM; Winkelmann RR; Cebulla CM; Abdel-Rahman MH; Campbell SM
    Int J Dermatol; 2014 Jun; 53(6):657-63. PubMed ID: 24697775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families.
    Njauw CN; Kim I; Piris A; Gabree M; Taylor M; Lane AM; DeAngelis MM; Gragoudas E; Duncan LM; Tsao H
    PLoS One; 2012; 7(4):e35295. PubMed ID: 22545102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.
    Helgadottir H; Höiom V; Tuominen R; Nielsen K; Jönsson G; Olsson H; Hansson J
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27287845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature.
    Haugh AM; Njauw CN; Bubley JA; Verzì AE; Zhang B; Kudalkar E; VandenBoom T; Walton K; Swick BL; Kumar R; Rana HQ; Cochrane S; McCormick SR; Shea CR; Tsao H; Gerami P
    JAMA Dermatol; 2017 Oct; 153(10):999-1006. PubMed ID: 28793149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Single Center Retrospective Review of Patients from Central Italy Tested for Melanoma Predisposition Genes.
    De Simone P; Bottillo I; Valiante M; Iorio A; De Bernardo C; Majore S; D'Angelantonio D; Valentini T; Sperduti I; Piemonte P; Eibenschutz L; Ferrari A; Carbone A; Buccini P; Paiardini A; Silipo V; Frascione P; Grammatico P
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33322357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
    Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
    J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma.
    Ewens KG; Lalonde E; Richards-Yutz J; Shields CL; Ganguly A
    BMC Cancer; 2018 Nov; 18(1):1172. PubMed ID: 30477459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group.
    Soufir N; Avril MF; Chompret A; Demenais F; Bombled J; Spatz A; Stoppa-Lyonnet D; Bénard J; Bressac-de Paillerets B
    Hum Mol Genet; 1998 Feb; 7(2):209-16. PubMed ID: 9425228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.
    Helsing P; Nymoen DA; Ariansen S; Steine SJ; Maehle L; Aamdal S; Langmark F; Loeb M; Akslen LA; Molven A; Andresen PA
    Genes Chromosomes Cancer; 2008 Feb; 47(2):175-84. PubMed ID: 18023021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.